- Home
- ARVN
ARVN
Arvinas Inc.
as 02-21-2025 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $58.82 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.61 - $51.51 | Next Earning Date: | 02-11-2025 |
| Revenue: | $263,399,999 | Revenue Growth: | 235.54% |
| Revenue Growth (this year): | -16.66% | Revenue Growth (next year): | 1.63% |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago
Zacks
8 days ago
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
Zacks
8 days ago
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
MT Newswires
10 days ago
Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating
Thomson Reuters StreetEvents
10 days ago
Q4 2024 Arvinas Inc Earnings Call
GuruFocus.com
10 days ago
Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...
Zacks
11 days ago
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
MT Newswires
11 days ago
Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.